138 related articles for article (PubMed ID: 27684044)
1. Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema.
Zeynalov E; Jones SM; Elliott JP
J Vis Exp; 2016 Sep; (115):. PubMed ID: 27684044
[TBL] [Abstract][Full Text] [Related]
2. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice.
Zeynalov E; Jones SM; Seo JW; Snell LD; Elliott JP
PLoS One; 2015; 10(8):e0136121. PubMed ID: 26275173
[TBL] [Abstract][Full Text] [Related]
3. Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4.
Nakayama S; Amiry-Moghaddam M; Ottersen OP; Bhardwaj A
Neurocrit Care; 2016 Apr; 24(2):273-82. PubMed ID: 26732270
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice.
Zeynalov E; Jones SM; Elliott JP
PLoS One; 2017; 12(8):e0183985. PubMed ID: 28854286
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Clinically Relevant Hypertonic Saline and Conivaptan Administration on Ischemic Stroke.
Decker D; Collier L; Lau T; Olivera R; Roma G; Leonardo C; Seifert H; Rowe D; Pennypacker KR
Acta Neurochir Suppl; 2016; 121():243-50. PubMed ID: 26463956
[TBL] [Abstract][Full Text] [Related]
6. Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature.
Hedna VS; Bidari S; Gubernick D; Ansari S; Satriotomo I; Khan AA; Qureshi AI
BMC Neurol; 2014 Nov; 14():213. PubMed ID: 25403760
[TBL] [Abstract][Full Text] [Related]
7. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
Krieg SM; Sonanini S; Plesnila N; Trabold R
J Neurotrauma; 2015 Feb; 32(4):221-7. PubMed ID: 25111427
[TBL] [Abstract][Full Text] [Related]
8. Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke.
Liu X; Nakayama S; Amiry-Moghaddam M; Ottersen OP; Bhardwaj A
Neurocrit Care; 2010 Feb; 12(1):124-31. PubMed ID: 19806476
[TBL] [Abstract][Full Text] [Related]
9. Conivaptan for hyponatremia in the neurocritical care unit.
Wright WL; Asbury WH; Gilmore JL; Samuels OB
Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
[TBL] [Abstract][Full Text] [Related]
10. Intravenous conivaptan.
Moen MD; Keating GM
Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients withchronic heart failure during submaximal exercise.
Balling L; Thomsen JH; Wolsk E; Hassager C; Boesgaard S; Goldsmith SR; Gustafsson F
Am Heart J; 2018 Sep; 203():101-104. PubMed ID: 30057012
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
Goldsmith SR; Elkayam U; Haught WH; Barve A; He W
J Card Fail; 2008 Oct; 14(8):641-7. PubMed ID: 18926434
[TBL] [Abstract][Full Text] [Related]
13. Arginine vasopressin V1a receptor-deficient mice have reduced brain edema and secondary brain damage following traumatic brain injury.
Rauen K; Trabold R; Brem C; Terpolilli NA; Plesnila N
J Neurotrauma; 2013 Aug; 30(16):1442-8. PubMed ID: 23441636
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tanaka A; Iizumi Y; Honda K
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():113P-117P. PubMed ID: 10629866
[TBL] [Abstract][Full Text] [Related]
15. A New Role for Conivaptan in Ulcerative Colitis in Mice: Inhibiting Differentiation of CD4
Dou D; Ji Y; Zheng J; Li J; Zhu X; Tang S; Wang H; Li Q; Jing H
Dig Dis Sci; 2022 Aug; 67(8):3683-3692. PubMed ID: 34751838
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.
Wada K; Fujimori A; Matsukawa U; Arai Y; Sudoh K; Yatsu T; Sasamata M; Miyata K
Eur J Pharmacol; 2005 Jan; 507(1-3):145-51. PubMed ID: 15659304
[TBL] [Abstract][Full Text] [Related]
18. The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury.
Kleindienst A; Dunbar JG; Glisson R; Marmarou A
Acta Neurochir (Wien); 2013 Jan; 155(1):151-64. PubMed ID: 23188468
[TBL] [Abstract][Full Text] [Related]
19. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
[TBL] [Abstract][Full Text] [Related]
20. Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers.
Lasseter KC; Dilzer SC; Smith N
Adv Ther; 2007; 24(2):310-8. PubMed ID: 17565921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
